Bioventus Inc (BVS) Fair Value & Analysis
Healthcare · US · Market cap $598M
Bioventus Inc
BVS · US
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Share price +14.9% over the past month.
Price vs Fair Value (12 months)
12‑month range $5.83 – $10.39 · fair‑value band $5.54 – $10.77 · the $9.29 price screens above the $7.40 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Bioventus Inc (BVS) currently trades at $9.29, while our model-based Fair Value estimate is $7.40 — implying the stock looks roughly 20.3% overvalued today. We read business quality at 85/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, Bioventus Inc generated revenue of $576M at a net margin of 4.9%. Revenue grew 6.6% year over year. It earns a return on equity of 16.5%. Net debt stands at $260M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. I…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bioventus Inc reported revenue of $568M in FY2025 versus $431M in FY2021, a compound +7.2%/yr. Reported net income was $22.7M in FY2025, compounding +4.1%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,228 MXN | -23% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bioventus Inc (BVS) undervalued?
What is the fair value of BVS?
What is the quality score of BVS?
What is the revenue of Bioventus Inc (BVS)?
What is the net profit margin of BVS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.